Treatment of raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor
β Scribed by James R. Seibold; Anton H. M. Jageneau
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 787 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Treatment with conventional antipsychotic drugs (APDs) is accompanied by extrapyramidal side effects (EPS), which are thought to be due to striatal dopamine D(2) receptor blockade. In contrast, treatment with atypical APDs is marked by a low incidence or absence of EPS. The reduced motor side effect
## Abstract Fβ18 labeled SR46349B, a highly potent and selective 5βHT~2~ receptor antagonist, was synthesized as a potential radioligand for PET studies of brain 5βHT~2~ receptors. Nucleophilic aromatic substitution of __trans__β1β(2βnitrophenyl)β3β(4βmethoxymethoxyphenyl)β2βpropenone (10) with NCA